Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Natalia B. Bulieva"'
Autor:
Vladimir I. Vorobyev, Eduard G. Gemdzhian, Liudmila V. Fedorova, Natalia B. Mikhailova, Ridvan K. Ilyasov, Liliia P. Kaleikina, Olga S. Trubyakova, Kamil D. Kaplanov, Elena V. Melnichenko, Elena V. Martynova, Elena P. Yakovleva, Olga Yu. Li, Elena V. Tarasenko, Elena P. Chumakova, Natalia B. Bulieva, Ekaterina S. Nesterova, Oleg V. Margolin, Vera A. Zherebtsova, Lev S. Butaev, Vadim V. Ptushkin
Publikováno v:
Терапевтический архив, Vol 93, Iss 7, Pp 770-777 (2021)
Background. Mantle cell lymphoma (MCL) is a rare and clinically aggressive lymphoma subtype. Current approaches have greatly improved patients outcomes, but relapse is inevitable. In phase IIIII clinical trials, ibrutinib has shown significant activi
Externí odkaz:
https://doaj.org/article/b83a79daf0fc4b7db69564adb35219aa
Autor:
Liudmila V. Fedorova, Elena V. Melnichenko, Kaplanov Kd, Elena V. Martynova, Vladimir I. Vorobyev, Natalia B. Mikhailova, Liliia P. Kaleikina, Natalia B. Bulieva, Olga S. Trubyakova, Elena P. Yakovleva, Elena P. Chumakova, Elena V. Tarasenko, Vadim V. Ptushkin, Olga Yu. Li, Lev S. Butaev, Ridvan K. Ilyasov, E S Nesterova, Vera A. Zherebtsova, Margolin Ov, Eduard G. Gemdzhian
Publikováno v:
Терапевтический архив, Vol 93, Iss 7, Pp 770-777 (2021)
Mantle cell lymphoma (MCL) is a rare and clinically aggressive lymphoma subtype. Current approaches have greatly improved patients outcomes, but relapse is inevitable. In phase IIIII clinical trials, ibrutinib has shown significant activity in patien